{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical information and guidelines for healthcare professionals.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>CUSHING'S SYNDROME<|>EVENT<|>Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol.)\n##\n(\"entity\"<|>CRH TEST<|>EVENT<|>The CRH test is a diagnostic procedure used to evaluate the cause of Cushing's syndrome by measuring ACTH and cortisol levels.)\n##\n(\"relationship\"<|>UPTODATE INC.<|>WALTHAM<|>UpToDate Inc. is based in Waltham, Massachusetts, providing medical information from this location.<|>7)\n##\n(\"relationship\"<|>CUSHING'S SYNDROME<|>CRH TEST<|>The CRH test is utilized for diagnosing Cushing's syndrome by assessing hormonal responses.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , eds. UpToDate. Waltham, MA: UpToDate Inc.\n                                                                                                                                            https://www.uptodate.com (acceso 29 de abril de 2019).\n        tostatina. Por tanto, ejercerá su acción a nivel hipofisario, uniéndose a los receptores de so-\n        matostatina de las células corticotropas (sobre todo por su afinidad al subtipo 5 del recep-\n        tor de somatostatina), reduciendo la secreción de ACTH a ese nivel (respuesta C correcta).\n        Referencias:\n        • Nieman LK. Medical therapy of hypercortisolism (Cushing´s syndrome). En: Lacroix A, Martin KA, eds. UpToDate. Waltham, MA:\n          UpToDate Inc. https://www.uptodate.com (acceso 29 de abril de 2019).\n\n\n\n50                                                                                                                                                                                                                                                                51\n---\n                                                                                                                                                                                                                                                               HIPÓFISIS                         1\n\n\n\n    41  En relación con el test de CRH para el diagnóstico del síndrome de Cushing, indique                                                                     1.7 Deficiencia de hormona de crecimiento\n        cuál de las siguientes afirmaciones es correcta:\n        A. En sujetos normales, la administración de CRH ocasiona un aumento de cortisol                                                                                 En relación con el tratamiento con GH para la talla baja, indique cuál de las\n            y ACTH de más de un 100%.                                                                                                                              42\n        B. Una respuesta positiva del ACTH y del cortisol a la administración de CRH hace muy                                                                            siguientes afirmaciones es correcta:\n            improbable la posibilidad de síndrome de Cushing por ACTH ectópico.                                                                                          A. La GH se puede utilizar en el tratamiento de la talla baja por insensibilidad a la GH.\n        C. En la enfermedad de Cushing, el aumento de cortisol y ACTH tras la administración                                                                             B. La GH se puede utilizar en el tratamiento de la talla baja por enfermedad renal crónica.\n            de CRH es prácticamente nulo en la mayoría de los casos.                                                                                                     C. La monitorización de los niveles de IGF-1 no tiene utilidad en el seguimiento del\n        D.  Este test se utiliza fundamentalmente para diferenciar el síndrome de Cushing por                                                                                 tratamiento con GH.\n            ACTH ectópico del originado por adenoma o carcinoma suprarrenal.                                                                                             D.   La hipoglucemia es un efecto secundario frecuente del tratamiento con GH.\n\n\n\n        COMENTARIO                                                                                                                                                       COMENTARIO\n        Test de CRH: utilidad, interpretación y limitaciones                                                                                                               Las indicaciones de tratamiento con                  GH oficialmente aprobadas en               nuestro medio\n        El test de CRH se utiliza para el diagnóstico etiológico del síndrome de Cushing dependiente                                                                       para el tratamiento en el niño son:\n        de ACTH, con el objetivo de diferenciar entre la producción hipofisaria y ectópica de ACTH                                                                         •   Déficit clásico o defecto de la hormona de crecimiento.\n        (no entre Cushing dependiente o independiente de ACTH, como sugiere la respuesta D).                                                                               •   2. Síndrome de Turner.\n        En individuos sanos, las concentraciones de ACTH se incrementan un 50% y las de cortisol,                                                                          •   3. Insuficiencia renal crónica, en niños en período prepuberal (respuesta B correcta).\n        un 20% (respuesta A incorrecta). En la secreción ectópica de ACTH la respuesta es menor                                                                            •   4. Síndrome de Prader-Willi.\n        (respuesta B correcta) y en la enfermedad de Cushing se observa una hiperrespuesta, ya                                                                             •   5. Crecimiento intrauterino retardado.\n        que las células corticotropas tumorales conservan cierto grado de respuesta al estímulo\n        con CRH. Una elevación superior a un 50% en los niveles de ACTH y/o superior al 20% en                                                                             •   6. Deficiencia de crecimiento debida a alteración del gen SHOX.\n        los niveles de cortisol, tras la inyección intravenosa de CRH (100 µg), es sugestiva de enfer-                                                                   Para el síndrome de Noonan y la talla baja idiopática están autorizados en Estados Unidos,\n        medad de Cushing (respuesta C incorrecta).                                                                                                                       pero no en España.\n        Sin embargo, hay que tener en cuenta algunas limitaciones:                                                                                                       El síndrome de        insensibilidad a la      GH o síndrome de Laron no sería tratable con GH. Se\n        •  Hasta en un 10% de pacientes con enfermedad de Cushing la respuesta de ACTH en este                                                                           caracteriza por una mutación en el gen del receptor de GH y los pacientes tienen niveles\n           test es inferior al 50%, independientemente de que se trate de micro- o macroadenomas.                                                                        elevados de GH con IGF-1 muy baja. El tratamiento se realizaría con IGF-1 puesto que la\n           Esto quizá se pueda relacionar con el uso en Europa de CRH humano, menos potente que                                                                          alteración del receptor hace que la GH recombinante sea ineficaz (respuesta A).\n           el ovino, con el que se\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}